Skip to main content

Advertisement

SpringerLink
Log in

Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature

  • Review
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Economic evaluations are increasingly being used by decision-makers to estimate the cost-effectiveness of interventions. The objective of this study was to conduct a structured review of economic evaluations of interventions to prevent and treat osteoporosis. Articles were identified independently by two reviewers through searches on MEDLINE, the bibliographies of reviews and identified economic models, and expert opinion, using predefined inclusion and exclusion criteria. Data on country, type and level of interventions, type of fractures, interventions, study population and the authors’ stated conclusions were extracted. Forty-two relevant studies were identified. The majority of studies (71%) were conducted in Sweden, the UK and the US. The main interventions investigated were hormone replacement therapy (27%), bisphosphonates (17%) and combinations of vitamin D and calcium (16%). In 38% of studies, hip fracture was the sole fracture outcome. Eighty-eight percent (88%) of studies investigated female populations only. A relatively large number of economic evaluations were identified in the field of osteoporosis. Major changes have recently occurred in the treatment of this disease, following the publication of the results of the Women’s Health Initiative trial. Methodological developments in economic evaluations, such as the use of probabilistic sensitivity analysis and cost-effectiveness acceptability curves, have also taken place. Such changes are reflected in the studies that were reviewed. The development of economic models should be an iterative process that incorporates new information, whether clinical or methodological, as it becomes available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Taylor RS, Drummond MF, Salkeld G, Sullivan SD (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329: 972–975

    Article  CAS  PubMed  Google Scholar 

  2. Fleurence RL, Iglesias CP, Torgerson DJ (2003) Cost-effectiveness of nutritional supplements for the treatment of osteoporosis. In: Bonjour JP, New S (eds) Nutritional aspects of bone health. Royal Society of Chemistry, London, pp 693–708

  3. Fleurence RL, Iglesias CP, Torgerson DJ (2005) Economic aspects of osteoporosis treatment. In Cooper C, Lindsay R (eds) The prevention and treatment of osteoporosis in the high-risk patient. Martin Dunitz, London, pp 81–102

  4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  PubMed  CAS  Google Scholar 

  5. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, et al (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 289:2673–2684

    Article  CAS  PubMed  Google Scholar 

  6. Anderson GL, Limacher M, Assaf AR, Bassford T, et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712

    Article  CAS  PubMed  Google Scholar 

  7. Birks YF, Porthouse J, Addie C, Loughney K, et al (2004) Randomized controlled trial of hip protectors among women living in the community. Osteoporos Int 15:701–706

    Article  PubMed  Google Scholar 

  8. Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469

    Article  CAS  PubMed  Google Scholar 

  9. Porthouse J, Cockayne S, King C, Saxon L, et al (2005) Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ (in press)

  10. The RECORD Trial Group (2005). Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet (in press)

  11. Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S, et al (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841–857

    Article  CAS  PubMed  Google Scholar 

  12. Coyle D, Cranney A, Lee KM, Welch V, et al (2000) Cost-effectiveness research in osteoporosis. Drug Dev Res 49:135–140

    Article  CAS  Google Scholar 

  13. Johannesson M, Jonsson B (1993) Economic evaluation of osteoporosis prevention. Health Policy 24:103–124

    Article  CAS  PubMed  Google Scholar 

  14. Sculpher M, Torgerson D, Goeree R, O’Brien BJ (1999) A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis. CHE Discussion Paper 169, University of York, York

  15. Torgerson DJ, Reid DM (1997) The economics of osteoporosis and its prevention. A review. Pharmacoeconomics 11:126–138

    Article  CAS  PubMed  Google Scholar 

  16. Whittington R, Faulds D (1994) Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease. Pharmacoeconomics 5:513–554

    CAS  PubMed  Google Scholar 

  17. Cheung AP, Wren BG (1992) A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 156:312–316

    CAS  PubMed  MathSciNet  Google Scholar 

  18. Tosteson AN, Rosenthal DI, Melton III LJ, Weinstein MC (1990) Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 113:594–603

    CAS  PubMed  Google Scholar 

  19. Tosteson AN, Weinstein MC (1991) Cost-effectiveness of hormone replacement therapy after the menopause. Bailliere’s Clin Obstetr Gynaecol 5:943–959

    Google Scholar 

  20. Weinstein MC (1980) Estrogen use in postmenopausal women—costs, risks, and benefits. N Engl J Med 303:308–316

    Article  CAS  PubMed  Google Scholar 

  21. Weinstein MC, Schiff I (1983) Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 38:445–455

    CAS  PubMed  Google Scholar 

  22. Weinstein MC, Tosteson AN (1990) Cost-effectiveness of hormone replacement. Ann N Y Acad Sci 592:162–172

    CAS  PubMed  ADS  Google Scholar 

  23. Jonsson B, Kanis J, Dawson A, Oden A, et al (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193–199

    Article  CAS  PubMed  Google Scholar 

  24. Kanis JA, Dawson A, Oden A, Johnell O, et al (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12:356–361

    Article  CAS  PubMed  Google Scholar 

  25. Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365

    CAS  PubMed  Google Scholar 

  26. Fleurence RL, Torgerson DJ, Reid DM (2002) Cost-effectiveness of hormone replacement therapy for fracture prevention in young postmenopausal women: an economic analysis based on a prospective cohort study. Osteoporos Int 13:637–643

    Article  CAS  PubMed  Google Scholar 

  27. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, et al (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6:217–227

    Article  CAS  PubMed  Google Scholar 

  28. Sculpher M, Fenwick E, Claxton K (2000) Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 17:461–477

    Article  CAS  PubMed  Google Scholar 

  29. Tosteson AN, Jonsson B, Grima DT, O’Brien BJ, et al (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849–857

    Article  CAS  PubMed  Google Scholar 

  30. Borgstrom F, Johnell O, Jonsson B, Zethraeus N, et al (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34:1064–1071

    Article  PubMed  Google Scholar 

  31. Fleurence RL (2004) The cost-effectiveness of fracture prevention treatments in the elderly. Int J Technol Assess Health Care 20:184–191

    Article  PubMed  Google Scholar 

  32. Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. QJM 95:305–311

    Article  CAS  PubMed  Google Scholar 

  33. Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862–871

    Article  CAS  PubMed  Google Scholar 

  34. Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15–25

    Article  CAS  PubMed  Google Scholar 

  35. Torgerson DJ, Bell-Syer SE (2001) Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285:2891–2897

    Article  CAS  PubMed  Google Scholar 

  36. Manson JE, Hsia J, Johnson KC, Rossouw JE, et al (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523–534

    Article  CAS  PubMed  Google Scholar 

  37. Majumdar SR, Almasi EA, Stafford RS (2004) Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA 292:1983–1988

    Article  CAS  PubMed  Google Scholar 

  38. Grady D (2003) Postmenopausal hormones—therapy for symptoms only. N Engl J Med 348:1835–1837

    Article  PubMed  Google Scholar 

  39. Black DM, Cummings SR, Karpf DB, Cauley JA, et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541

    Article  CAS  PubMed  Google Scholar 

  40. Cummings SR, Eckert S, Krueger KA, Grady D, et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197

    Article  CAS  PubMed  Google Scholar 

  41. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645

    Article  CAS  PubMed  Google Scholar 

  42. Levis S, Quandt SA, Thompson D, Scott J, et al (2002) Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 50:409–415

    Article  PubMed  Google Scholar 

  43. Reginster J, Minne HW, Sorensen OH, Hooper M, et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91

    Article  CAS  PubMed  Google Scholar 

  44. Johnell O, Kanis J, Gullberg G (2001) Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif Tissue Int 69:182–184

    Article  CAS  PubMed  Google Scholar 

  45. Segui-Gomez M, Keuffel E, Frick KD (2002) Cost and effectiveness of hip protectors among the elderly. Int J Technol Assess Health Care 18:55–66

    PubMed  Google Scholar 

  46. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936

    Article  PubMed  Google Scholar 

  47. Stevenson MD, Oakley J, Chilcott JB (2004) Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making 24:89–100

    Article  CAS  PubMed  Google Scholar 

  48. Ankjaer-Jensen A, Johnell O (1996) Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 6:265–275

    Article  CAS  PubMed  Google Scholar 

  49. Armstrong K, Chen TM, Albert D, Randall TC, et al (2001) Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol 98:996–1003

    Article  CAS  PubMed  Google Scholar 

  50. Brecht JG, Kruse HP, Felsenberg D, Mohrke W, et al (2003) Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 23:93–105

    CAS  PubMed  Google Scholar 

  51. Brecht JG, Kruse HP, Mohrke W, Oestreich A, et al (2004) Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 24:1–10

    CAS  PubMed  Google Scholar 

  52. Colon-Emeric CS, Datta SK, Matchar DB (2003) An economic analysis of external hip protector use in ambulatory nursing facility residents. Age Ageing 32:47–52

    Article  PubMed  Google Scholar 

  53. Coyle D, Cranney A, Lee KM (2001) Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 19:565–575

    Article  CAS  PubMed  Google Scholar 

  54. Daly E, Roche M, Barlow D, Gray A, et al (1992) HRT: an analysis of benefits, risks and costs. Br Med Bull 48:368–400

    CAS  PubMed  Google Scholar 

  55. Daly E, Vessey MP, Barlow D, Gray A, et al (1996) Hormone replacement therapy in a risk-benefit perspective. Maturitas 23:247–259

    Article  CAS  PubMed  Google Scholar 

  56. Francis RM, Anderson FH, Torgerson DJ (1995) A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 34:1167–1171

    CAS  PubMed  Google Scholar 

  57. Garton MJ, Cooper C, Reid D (1997) Perimenopausal bone density screening—will it help prevent osteoporosis? Maturitas 26:35–43

    Article  CAS  PubMed  Google Scholar 

  58. Geelhoed E, Harris A, Prince R (1994) Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health 18:153–160

    Article  CAS  PubMed  Google Scholar 

  59. Hart WM, Rubio-Terres C, Burrell A, Aristegui I, et al (2002) Pharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronate. Revista Espanola de Enfermedades Metabolicas Oseas 11:97–104

    Google Scholar 

  60. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314

    Article  PubMed  Google Scholar 

  61. Jonsson B (1998) Targeting high-risk populations. Osteoporos Int 8 [Suppl 1]:S13–S16

  62. Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136–142

    Article  CAS  PubMed  Google Scholar 

  63. Kanis JA, Brazier JE, Stevenson M, Calvert NW, et al (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1–146

    CAS  PubMed  Google Scholar 

  64. Nagata-Kobayashi S, Shimbo T, Fukui T (2002) Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women. J Bone Miner Metab 20:350–357

    Article  PubMed  Google Scholar 

  65. Rodriguez EC, Fidalgo Garcia ML, Rubio CS (1999) A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture. Aten Primaria 24:390–396

    PubMed  Google Scholar 

  66. Rosner AJ, Grima DT, Torrance GW, Bradley C, et al (1998) Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 14:559–573

    Article  CAS  PubMed  Google Scholar 

  67. Singh S, Sun H, Anis AH (2004) Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents. J Rheumatol 31:1607–1613

    PubMed  Google Scholar 

  68. Torgerson D, Kanis JA (1995) Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJM 88:135–139

    CAS  PubMed  Google Scholar 

  69. Torgerson D, Donaldson C, Reid D (1996) Using economics to prioritize research: a case study of randomized trials for the prevention of hip fractures due to osteoporosis. J Health Serv Res Policy 1:141–146

    CAS  PubMed  Google Scholar 

  70. Visentin P, Ciravegna R, Fabris F (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26:185–192

    Article  CAS  PubMed  Google Scholar 

  71. Waldegger L, Cranney A, Man-Son-Hing M, Coyle D (2003) Cost-effectiveness of hip protectors in institutional dwelling elderly. Osteoporos Int 14:243–250

    PubMed  Google Scholar 

  72. Willis M, Odegaard K, Persson U, Mellstrom D, et al (2001) A cost-effectiveness model of tibolone as treatment for the prevention of osteoporosis fractures in postmenopausal women in Sweden. Clin Drug Invest 21:115–127

    Article  CAS  Google Scholar 

  73. Willis M (2002) The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden. Int J Technol Assess Health Care 18:791–807

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Eli Lilly for their financial support for part of this study.

Author information

Authors and Affiliations

  1. The MEDTAP Institute at UBC, Bethesda, MD, USA

    Rachael L. Fleurence

  2. Department of Health Sciences, University of York, York, UK

    Cynthia P. Iglesias & David J. Torgerson

  3. , 7101 Wisconsin Avenue, Suite 600, Bethesda, MD, 20814, USA

    Rachael L. Fleurence

Authors
  1. Rachael L. Fleurence
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cynthia P. Iglesias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J. Torgerson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachael L. Fleurence.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fleurence, R.L., Iglesias, C.P. & Torgerson, D.J. Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int 17, 29–40 (2006). https://doi.org/10.1007/s00198-005-1943-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-005-1943-z

Keywords

Search

Navigation